JHEP Reports

Papers
(The TQCC of JHEP Reports is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper308
Limitations of non-invasive tests for assessment of liver fibrosis116
Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic105
Non-alcoholic fatty liver disease: A patient guideline97
NAFLD and liver transplantation: Disease burden, current management and future challenges85
Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial76
Beta-blockers in cirrhosis: Evidence-based indications and limitations75
Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment75
Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors74
Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma73
Organoids to model liver disease67
New targets for NAFLD66
Lipid alterations in chronic liver disease and liver cancer60
Where does TIPS fit in the management of patients with cirrhosis?57
Artificial intelligence in liver diseases: Improving diagnostics, prognostics and response prediction55
Single-cell RNA sequencing of human liver reveals hepatic stellate cell heterogeneity52
Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study49
The liver matrisome – looking beyond collagens48
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area48
ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma48
Novel vectors and approaches for gene therapy in liver diseases48
Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease47
NAFLD and MAFLD as emerging causes of HCC: A populational study47
Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy46
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg45
Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B45
Gut dysbiosis as a driver in alcohol-induced liver injury43
Granulocyte colony-stimulating factor for alcoholic hepatitis: A systematic review and meta-analysis of randomised controlled trials42
New frontiers in liver resection for hepatocellular carcinoma38
Our emerging understanding of the roles of long non-coding RNAs in normal liver function, disease, and malignancy36
Liver fibrosis and CD206+ macrophage accumulation are suppressed by anti-GM-CSF therapy36
Combined alcoholic and non-alcoholic steatohepatitis34
Assessing the impact of COVID-19 on liver cancer management (CERO-19)34
Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD33
Extended hypothermic oxygenated machine perfusion enables ex situ preservation of porcine livers for up to 24 hours33
Higher phenolic acid intake independently associates with lower prevalence of insulin resistance and non-alcoholic fatty liver disease33
Body composition predicts mortality and decompensation in compensated cirrhosis patients: A prospective cohort study33
Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases32
Nuclear deformation mediates liver cell mechanosensing in cirrhosis31
Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis30
miR-22 inhibition reduces hepatic steatosis via FGF21 and FGFR1 induction29
Understanding the cellular interactome of non-alcoholic fatty liver disease29
Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation29
Real-world experience with obeticholic acid in patients with primary biliary cholangitis29
De novo synthesis of hepatitis B virus nucleocapsids is dispensable for the maintenance and transcriptional regulation of cccDNA29
Evaluating causality of cellular senescence in non-alcoholic fatty liver disease28
Evaluation of liver tumour response by imaging28
Cell of origin in biliary tract cancers and clinical implications28
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease28
Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis27
Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension26
Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD – Reconciling the present with the past26
Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD26
Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis26
Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS25
New insights on the role of vascular endothelial growth factor in biliary pathophysiology25
Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction25
Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis25
Transforming growth factor β latency: A mechanism of cytokine storage and signalling regulation in liver homeostasis and disease25
A human liver chimeric mouse model for non-alcoholic fatty liver disease25
A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage25
The ALBI score: From liver function in patients with HCC to a general measure of liver function24
Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation24
Approach to the patient with acute severe autoimmune hepatitis24
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-224
European ‘NAFLD Preparedness Index’ — Is Europe ready to meet the challenge of fatty liver disease?24
Bile acids contribute to the development of non-alcoholic steatohepatitis in mice24
Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis23
NASH-related increases in plasma bile acid levels depend on insulin resistance23
Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic review23
Exposure to perfluoroalkyl substances and risk of hepatocellular carcinoma in a multiethnic cohort23
Adding the oxygen carrier M101 to a cold-storage solution could be an alternative to HOPE for liver graft preservation22
Physical activity is associated with reduced risk of liver disease in the prospective UK Biobank cohort22
Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma22
A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation22
Purinergic signalling in liver diseases: Pathological functions and therapeutic opportunities21
The neurogliovascular unit in hepatic encephalopathy21
Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D21
The role of cGAS-STING signalling in liver diseases21
Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets21
Influence of surgical approach and quality of resection on the probability of cure for early-stage HCC occurring in cirrhosis21
A dynamic association between myosteatosis and liver stiffness: Results from a prospective interventional study in obese patients20
New insights into the pathophysiology and clinical care of rare primary liver cancers20
Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey20
Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study20
Embedding assessment of liver fibrosis into routine diabetic review in primary care20
Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions20
Hepatitis B virus preS2Δ38–55 variants: A newly identified risk factor for hepatocellular carcinoma20
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance19
Using cell-free DNA for HCC surveillance and prognosis19
Stratification of patients in NASH clinical trials: A pitfall for trial success19
Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis19
Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed circular DNA19
Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis18
Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty liver disease in adolescents18
The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes18
Early transplantation maximizes survival in severe acute-on-chronic liver failure: Results of a Markov decision process model18
Efficient in vivo editing of OTC-deficient patient-derived primary human hepatocytes18
Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC18
Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication18
Volatomic analysis identifies compounds that can stratify non-alcoholic fatty liver disease18
Elevated plasma ICAM1 levels predict 28-day mortality in cirrhotic patients with COVID-19 or bacterial sepsis17
Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy17
Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities17
Case-finding strategies in non-alcoholic fatty liver disease17
Features and outcome of AIH patients without elevation of IgG17
Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity17
Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease17
TGR5 controls bile acid composition and gallbladder function to protect the liver from bile acid overload17
ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis17
Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer17
Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis16
Bile acid-receptor TGR5 deficiency worsens liver injury in alcohol-fed mice by inducing intestinal microbiota dysbiosis16
The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care16
Are the new genetic tools for diagnosis of Wilson disease helpful in clinical practice?16
Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines15
Similar performance of liver stiffness measurement and liver surface nodularity for the detection of portal hypertension in patients with hepatocellular carcinoma15
Novel role of macrophage TXNIP-mediated CYLD–NRF2–OASL1 axis in stress-induced liver inflammation and cell death15
Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine15
Non-invasive biomarkers of Fontan-associated liver disease15
Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection15
Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B15
TNF-alpha inhibition ameliorates HDV-induced liver damage in a mouse model of acute severe infection14
Epidemiology of autosomal-dominant polycystic liver disease in Olmsted county14
XBP1-mediated activation of the STING signalling pathway in macrophages contributes to liver fibrosis progression14
Hepatic microbiome in healthy lean and obese humans14
Abnormal liver tests in patients with SARS-CoV-2 or influenza – prognostic similarities and temporal disparities14
Genetic or pharmacological reduction of cholangiocyte senescence improves inflammation and fibrosis in the Mdr2 mouse14
From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management?14
Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure14
Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates14
Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis13
Histological and serological features of acute liver injury after SARS-CoV-2 vaccination13
Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections13
Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis13
Hepatic miR-192-3p reactivation alleviates steatosis by targeting glucocorticoid receptor13
Hepatopulmonary syndrome13
Epigenetics of alcohol-related liver diseases13
Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank13
Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials13
Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators13
ZBTB20 regulates WNT/CTNNB1 signalling pathway by suppressing PPARG during hepatocellular carcinoma tumourigenesis13
High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma12
Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event12
Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis12
Treating hepatitis D with bulevirtide – Real-world experience from 114 patients12
Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis11
Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy11
Cell fate analysis of zone 3 hepatocytes in liver injury and tumorigenesis11
Ablation of liver Fxr results in an increased colonic mucus barrier in mice11
Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis11
Clinical and genetic determinants of the fatty liver–coagulation balance interplay in individuals with metabolic dysfunction11
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis11
Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis11
Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade11
Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice11
Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: A hybrid meta-analysis10
Impaired SARS-CoV-2-specific T-cell reactivity in patients with cirrhosis following mRNA COVID-19 vaccination10
A multicenter analysis of the role of prophylactic transfusion of blood products in patients with cirrhosis and esophageal varices undergoing endoscopic band ligation10
Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome10
Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C10
Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness10
Management of splanchnic vein thrombosis10
Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system10
IgG4/IgG RNA ratio does not accurately discriminate IgG4-related disease from pancreatobiliary cancer10
Abnormal brain oxygen homeostasis in an animal model of liver disease10
Low HDL-cholesterol levels predict hepatocellular carcinoma development in individuals with liver fibrosis10
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma10
Cellular origins of regenerating liver and hepatocellular carcinoma10
Profiling circulating microRNAs in patients with cirrhosis and acute-on-chronic liver failure10
Hepatic decompensation is accelerated in patients with cirrhosis and alpha-1 antitrypsin Pi∗MZ genotype9
Association of per- and polyfluoroalkyl substance exposure with fatty liver disease risk in US adults9
CRISPR-targeted genome editing of human induced pluripotent stem cell-derived hepatocytes for the treatment of Wilson’s disease9
Evidence for long-term association of virion-delivered HBV core protein with cccDNA independently of viral protein production9
International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria9
Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD9
Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection9
Higher subcutaneous adipose tissue radiodensity is associated with increased mortality in patients with cirrhosis9
Spleen volume-based non-invasive tool for predicting hepatic decompensation in people with compensated cirrhosis (CHESS1701)9
Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis9
Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis9
(13C)-Methacetin breath test provides evidence of subclinical liver dysfunction linked to fat storage but not lifestyle9
Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p9
Molecular characterization of chronic liver disease dynamics: From liver fibrosis to acute-on-chronic liver failure9
0.05516505241394